AU5451598A - Transport of liposomes across the blood-brain barrier - Google Patents

Transport of liposomes across the blood-brain barrier

Info

Publication number
AU5451598A
AU5451598A AU54515/98A AU5451598A AU5451598A AU 5451598 A AU5451598 A AU 5451598A AU 54515/98 A AU54515/98 A AU 54515/98A AU 5451598 A AU5451598 A AU 5451598A AU 5451598 A AU5451598 A AU 5451598A
Authority
AU
Australia
Prior art keywords
liposomes
blood
transport
brain barrier
brain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU54515/98A
Inventor
Jorg Huwyler
William M. Pardridge
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California filed Critical University of California
Publication of AU5451598A publication Critical patent/AU5451598A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A61K47/6913—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome the liposome being modified on its surface by an antibody

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Dispersion Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AU54515/98A 1996-11-22 1997-11-20 Transport of liposomes across the blood-brain barrier Abandoned AU5451598A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3163696P 1996-11-22 1996-11-22
US60031636 1996-11-22
PCT/US1997/021352 WO1998022092A1 (en) 1996-11-22 1997-11-20 Transport of liposomes across the blood-brain barrier

Publications (1)

Publication Number Publication Date
AU5451598A true AU5451598A (en) 1998-06-10

Family

ID=21860581

Family Applications (1)

Application Number Title Priority Date Filing Date
AU54515/98A Abandoned AU5451598A (en) 1996-11-22 1997-11-20 Transport of liposomes across the blood-brain barrier

Country Status (2)

Country Link
AU (1) AU5451598A (en)
WO (1) WO1998022092A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101086533B1 (en) 2002-05-24 2011-11-23 쉐링 코포레이션 Neutralizing human anti-IGFR antibody, a method for producing it and a composition comprising it
US7432331B2 (en) 2002-12-31 2008-10-07 Nektar Therapeutics Al, Corporation Hydrolytically stable maleimide-terminated polymers
EP1578842B1 (en) 2002-12-31 2009-10-07 Nektar Therapeutics Al, Corporation Hydrolytically stable maleimide-terminated polymers
NZ541760A (en) * 2003-02-10 2008-09-26 To Bbb Holding B V Differentially expressed nucleic acids in the blood-brain barrier under inflammatory conditions
EP1618897A4 (en) * 2003-04-04 2010-09-29 Eisai R&D Man Co Ltd Lipid membrane structure containing anti-mt-mmp monoclonal antibody
EP1694850B1 (en) 2003-11-12 2011-06-29 Schering Corporation Plasmid system for multigene expression
TW200526684A (en) 2003-11-21 2005-08-16 Schering Corp Anti-IGFR1 antibody therapeutic combinations
PT1828249E (en) 2004-12-03 2011-02-25 Schering Corp Biomarkers for pre-selection of patients for anti-igf1r therapy
WO2006126208A2 (en) * 2005-05-26 2006-11-30 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions and methods using same for delivering agents into a target organ protected by a blood barrier
TWI472348B (en) 2009-12-30 2015-02-11 Ind Tech Res Inst Peptide for transmigration across blood brain barrier and delivery systems comprising the same
PT2646470T (en) 2010-11-30 2017-05-03 Hoffmann La Roche Low affinity anti-transferrin receptor antibodies and their use to transfer therapeutic scfv across the blood brain barrier

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5527528A (en) * 1989-10-20 1996-06-18 Sequus Pharmaceuticals, Inc. Solid-tumor treatment method
US5543390A (en) * 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US5455044A (en) * 1993-05-14 1995-10-03 Depotech Corporation Method for treating neurological disorders

Also Published As

Publication number Publication date
WO1998022092A1 (en) 1998-05-28

Similar Documents

Publication Publication Date Title
AU3613695A (en) Liposomal agents
AU6319698A (en) Liposomes containing active agents
AU3616295A (en) Pharmaceutically active substituted aromatic compounds
AU4477597A (en) New pharmaceutically active compounds
AU3283995A (en) Aerosol
AU2186797A (en) Pharmaceutically useful compounds
AU3427395A (en) Ketoprofen liposomes
AU3645397A (en) Anticancer agents
AU5451598A (en) Transport of liposomes across the blood-brain barrier
AU738809C (en) Novel liposomal active-principle vectors
AU3444797A (en) Modular dismountable box
AU3883997A (en) Improved barrier film structures
AU4330097A (en) Pharmaceutical compounds
AU3013097A (en) Transportation crawler
AU4143397A (en) New pharmaceutically active compounds
AU6793598A (en) Glycosylceramide-containing liposomes
AU4169897A (en) Pharmaceutical compounds
AU2316997A (en) Liposomal delivery system
AU2904497A (en) Shelter
AU4143297A (en) New pharmaceutically active compounds
AU5800998A (en) Purified eukaryotic-initiation factor 4e
AU1042899A (en) Castor
AU3265895A (en) Liposome preparation
AU6500698A (en) Glycoprotein for the protection of liposomes
GB9625917D0 (en) Liposomes